Transcription of Alnylam Forward Looking Statements
{{id}} {{{paragraph}}}
1 2022 Alnylam Pharmaceuticals, 2022 Alnylam PharmaceuticalsNathan (USA)Diagnosed with AHP2 Alnylam Forward Looking StatementsThispresentationcontainsforwar d-lookingstatementswithinthemeaningofSec tion27 AoftheSecuritiesActof1933andSection21 EoftheSecuritiesExchangeActof1934,includ ingexpectationsregardingouraspirationtob ecomealeadingbiotechcompanyandtheplanned achievementofour AlnylamP5x25 strategy,ourabilitytoattainfinancialself -sustainability,ourpreliminaryfourthquar terand2021fiscalyearglobalnetproductreve nueandpatientsontherapy,theprobabilityof successofourRNAitherapeuticsplatform.
Société Francophone du Nerf Périphérique Potential FDA Approval of Vutrisiran Early 2022 (PDUFA date April 14, 2022) Cemdisiran Phase 2 Data in IgA Nephropathy Early 2022 APOLLO-B Phase 3 Results with Patisiran Mid-2022 ALN-HSD Phase 1 Part B Topline Results in NASH Patients Mid-2022 Vutrisiran Biannual Dose Regimen Data Late 2022
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}